Maria J. De Herdt

ORCID: 0000-0003-1023-4751
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer-related gene regulation
  • Liver physiology and pathology
  • Head and Neck Cancer Studies
  • Cancer-related molecular mechanisms research
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Chromatin Remodeling and Cancer
  • Cancer Mechanisms and Therapy
  • Hedgehog Signaling Pathway Studies
  • Ear and Head Tumors
  • PI3K/AKT/mTOR signaling in cancer
  • Salivary Gland Tumors Diagnosis and Treatment
  • MicroRNA in disease regulation
  • Brain Tumor Detection and Classification
  • Cutaneous Melanoma Detection and Management
  • Mechanisms of cancer metastasis
  • Genetics and Neurodevelopmental Disorders
  • Melanoma and MAPK Pathways
  • Lung Cancer Research Studies
  • Lung Cancer Treatments and Mutations
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Genomics and Chromatin Dynamics
  • RNA modifications and cancer
  • Protein Degradation and Inhibitors
  • TGF-β signaling in diseases
  • Immunotherapy and Immune Responses

Erasmus MC
2016-2025

Erasmus University Rotterdam
2016-2024

Erasmus MC Cancer Institute
2017-2022

University Medical Center Utrecht
2012

The Netherlands Cancer Institute
2012

Radboud University Nijmegen
2012

Leiden University
2008

Current assessment of lymph node metastasis in patients with head and neck squamous cell carcinoma is not accurate enough to prevent overtreatment. The aim this study was validation a gene expression signature for distinguishing metastasizing (N+) from nonmetastasizing (N0) the oral cavity (OSCC) oropharynx (OPSCC) large multicenter cohort, using diagnostic DNA microarray Clinical Laboratory Improvement Amendments/International Organization Standardization-approved laboratory.A multigene...

10.1200/jco.2011.40.4509 article EN Journal of Clinical Oncology 2012-10-09

The depth of invasion (DOI) is considered an independent risk factor for occult lymph node metastasis in oral cavity squamous cell carcinoma (OCSCC). It used to decide whether elective neck dissection (END) indicated the case a clinically negative early stage (pT1/pT2). However, there no consensus on cut-off value DOI performing END. aim this study was determine clinical decision making END, by assessing association and OCSCC.A retrospective cohort conducted at Erasmus MC, University Medical...

10.3389/fonc.2021.628320 article EN cc-by Frontiers in Oncology 2021-03-12

The Nucleosome Remodeling and Deacetylase (NURD) complex is a key regulator of cell differentiation that has also been implicated in tumorigenesis. Loss the NURD subunit Deleted Oral Cancer 1 (DOC1) associated with human oral squamous carcinomas (OSCCs). Here, we show restoration DOC1 expression OSCC cells leads to reversal epithelial-mesenchymal transition (EMT). This caused by DOC1-dependent targeting repress transcriptional regulators EMT. recruitment drives extensive epigenetic...

10.1016/j.celrep.2017.06.020 article EN cc-by-nc-nd Cell Reports 2017-07-01

Phenotypic plasticity and inflammation, two well-established hallmarks of cancer, play key roles in local invasion distant metastasis by enabling the rapid adaptation tumor cells to dynamic micro-environmental changes. Here, we show that oral squamous carcinoma cell (OSCC), competition between NuRD SWI/SNF chromatin remodeling complexes plays a pivotal role regulating both epithelial-mesenchymal (EMP) inflammation. By perturbing these complexes, demonstrated their opposing downstream effects...

10.1093/jnci/djaf065 article EN cc-by JNCI Journal of the National Cancer Institute 2025-03-18

Regional lymph node metastasis is an important prognostic factor in head and neck squamous cell carcinoma (HNSCC) plays a decisive role the choice of treatment. Here, we present independent gene expression validation study metastasized versus non-metastasized HNSCC. We used dataset recently published by Roepman et al. as reference 11 HNSCC tumors dataset. Reference studies were performed on different microarray platforms with probe sets content. In addition to supervised gene-based analysis,...

10.1186/1471-2407-8-168 article EN cc-by BMC Cancer 2008-06-10

Tyrosine-kinase inhibitors of the hepatocyte growth factor receptor MET are under investigation for treatment hormone-refractory prostate cancer (HRPC) metastasis. Analysis protein expression and genetic alterations might contribute to therapeutic stratification patients. Our objective was investigate on protein, DNA RNA level in clinical at various stages progression. Expression analyzed hormone-naive primary cancers (N=481), lymph node (N=40) bone (N=8) metastases, as well HRPC (N=54)...

10.18632/oncotarget.8829 article EN Oncotarget 2016-04-18

Cyclin-dependent kinase 2-associated protein 1 (CDK2AP1; also known as deleted in oral cancer or DOC1) is a tumor suppressor gene to play functional roles both cell cycle regulation and the epigenetic control of embryonic stem differentiation, latter core subunit nucleosome remodeling histone deacetylation (NuRD) complex. In vast majority squamous carcinomas (OSCC), expression CDK2AP1 reduced lost. Notwithstanding (and DOC1 acronym), mutations deletions its coding sequence are extremely...

10.1038/s41419-023-05857-2 article EN cc-by Cell Death and Disease 2023-05-22

Although the receptor tyrosine kinase (RTK) MET is widely expressed in head and neck squamous cell carcinoma (HNSCC), its prognostic value remains unclear. This might be due to use of a variety antibodies scoring systems. Here, reliability five commercial C-terminal (D1C2, CVD13, SP44, C-12 C-28) was evaluated before examining immunoreactivity HNSCC. Using cancer lines, it shown that D1C2 CVD13 specifically detect under reducing, native formalin-fixed paraffin-embedded (FFPE) conditions....

10.18632/oncotarget.7534 article EN Oncotarget 2016-02-20

MET positivity is independently associated with survival in oral squamous cell carcinoma (OSCC). Since a known orchestrator of invasive tumor growth, we investigated its association LNM early tongue (OTSCC). As it recommended by the NCCN to use depth invasion (DOI) making decisions on elective neck dissection (END), results obtained for were aligned those DOI > 4 mm. The cutoff value used our institution.Tumor samples from patients who underwent primary resection and between 1995 2013,...

10.3389/fonc.2021.638048 article EN cc-by Frontiers in Oncology 2021-04-29

Using tissue microarrays, it was shown that membranous C-terminal MET immunoreactivity and ectodomain (ECD) shedding are associated with poor prognosis in oral cancer. Seen the potential diagnostic value, extrapolation of these results to whole-tissue sections investigated. Because orchestrates epithelial-to-mesenchymal transition (EMT), were benchmarked loss E-cadherin, a readout for EMT known be prognosis. MET, N-terminal E-cadherin immunoreactivities examined on formalin-fixed...

10.1016/j.humpath.2020.07.018 article EN cc-by Human Pathology 2020-07-20

Abstract Phenotypic plasticity and inflammation, two well-established hallmarks of cancer, play key roles in local invasion distant metastasis by enabling rapid adaptation tumor cells to dynamic micro- environmental changes. Here, we show that oral squamous carcinoma cell (OSCC), the competition between NuRD SWI/SNF chromatin remodeling complexes plays a pivotal role regulating both epithelial-mesenchymal (EMP) inflammation. By perturbing these complexes, demonstrate their opposing...

10.1101/2024.04.05.588102 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2024-04-07

The receptor tyrosine kinase MET has gained attention as a therapeutic target. Although immunoreactivity is associated with progressive disease, use of targeted therapies not yet led to major survival benefits. A possible explanation the lack companion diagnostics (CDx) that account for proteolytic processing. During presenilin-regulated intramembrane proteolysis, MET's ectodomain shed into extracellular space, which followed by γ-secretase-mediated cleavage residual membranous C-terminal...

10.3390/cancers14061491 article EN Cancers 2022-03-15

Patients with cutaneous melanoma and a positive sentinel node (SN) are currently eligible for adjuvant treatment targeted therapy immune checkpoint inhibitors. Near-infrared (NIR) fluorescence imaging could be an alternative less invasive tool SN biopsy to select patients treatment. One potential target NIR is the mesenchymal-epithelial transition factor (MET). This study aimed assess MET immunoreactivity in SNs evaluate its diagnostic, prognostic therapeutic value.In this retrospective...

10.1016/j.anndiagpath.2022.151909 article EN cc-by Annals of Diagnostic Pathology 2022-02-07
Coming Soon ...